Trial Profile
Lacrimal Stability Evaluation (Three-Dimensional Image Analysis of Anterior Segment) with Rebamipide Ophthalmic Solution
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- 29 Oct 2017 Status changed from recruiting to discontinued.
- 30 Oct 2015 Number of treatment arms changed from 1 to 2, as reported by University Hospital Medical Information Network - Japan.
- 30 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.